Quintrio
Home

PHARMACEUTICAL PREPARATIONS

ALX Oncology Holdings Inc. Common Stock

ALXO

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Last trade $1.01
Day change +$0.005 (+0.50%)
Day range $0.956 – $1.03
Volume 264,747
Market cap $138M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$138.28M
Price / earnings
—
Price / book
1.02×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.52×

Profitability

Earnings per share
-$0.58
Return on assets
-50.3%
Return on equity
-59.4%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.07×
Current ratio
9.71×
Quick ratio
9.71×
Cash ratio
1.54×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$70.95M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALXO, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$5.13M$5.36M$5.38M$5.09M$5.45M$7.93M$7.08M$6.1M
Research and development$13.14M$13.61M$17.65M$17.44M$18.02M$23.89M$23.53M$26.47M
Total operating expenses$18.03M$18.97M$23.02M$22.53M$26.65M$31.82M$30.61M$32.57M
Operating income-$18.03M-$18.97M-$23.02M-$22.53M-$26.65M-$31.82M-$30.61M-$32.57M
Interest expense-$285K-$331K-$383K-$408K-$405K-$406K-$427K-$446K
Income before taxes-$17.97M-$17.93M-$22.85M-$22.14M-$25.95M-$30.75M-$29.16M-$30.71M
Income taxes$0$0$0$0$0$0$0$0
Net income-$17.97M-$17.93M-$22.85M-$22.14M-$25.95M-$30.75M-$29.16M-$30.71M
Net income attributable to common shareholders-$17.97M-$17.93M-$22.85M-$22.14M-$25.95M-$30.75M-$29.16M-$30.71M
EBITDA-$18.19M-$18.82M-$22.87M-$22.38M-$23.28M-$31.61M-$30.4M-$32.34M
Basic earnings per share-$0.13-$0.17-$0.42-$0.41-$0.49-$0.58-$0.54-$0.58
Diluted earnings per share-$0.13-$0.17-$0.42-$0.41-$0.49-$0.58-$0.54-$0.58

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ALX Oncology reported Q4 2025 financial results with improved net losses and announced strong clinical progress for its lead candidates evorpacept and ALX2004. The company validated CD47 as a predictive biomarker for evorpacept response in cancer trials, completed a $150 million equity offering extending cash runway through H1 2028, and appointed Barbara Klencke as permanent Chief Medical Officer. Multiple clinical milestones are anticipated over the next 12-18 months.

GlobeNewswire Inc.

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

ALX Oncology announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, with CEO Jason Lettmann and CMO Barbara Klencke delivering a corporate presentation on January 15, 2026. The clinical-stage biotech company is advancing evorpacept, a CD47-inhibitor being evaluated across multiple cancer indications, and ALX2004, an EGFR-targeted antibody-drug conjugate in Phase 1 trials.

GlobeNewswire Inc.

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

ALX Oncology reported impressive results from a Phase 2 trial combining evorpacept with rituximab and lenalidomide in treating indolent non-Hodgkin lymphoma, achieving a 92% complete response rate and 100% overall response rate.

GlobeNewswire Inc.

ALX Oncology to Present at Upcoming Investor Conferences

ALX Oncology will participate in two healthcare conferences in November and December 2025, presenting their ongoing clinical-stage cancer therapies, including lead candidate evorpacept and new pipeline candidate ALX2004.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.